samedan logo
 
 
 
spacer
home > ebr > summer 2019 > leveraging novel therapeutics and diagnostic assays
PUBLICATIONS
European Biopharmaceutical Review

Leveraging Novel Therapeutics and Diagnostic Assays

Immunotherapy is far from a novel concept, and its history is intriguing. It all began in 1891 when Dr William B Coley attempted to creatively harness the patient’s immune system. William achieved durable complete remission in several types of malignancies to include sarcoma, lymphoma, and testicular carcinoma by injecting mixtures of live and attenuated bacteria into patients’ tumours. Needless to say, we have come a long way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marisa Pearce is Scientific Affairs Liaison at Molecular MD, an ICON company, and has over 10 years of experience in oncology biomarker test development. She has been involved in the planning and design of molecular tests across the continuum from translational research to clinical deployment. These efforts include research use only assays for solid tumour profiling to the commercialisation of companion diagnostics for minimal residual disease monitoring. Marisa's diverse background enables her to serve as subject matter expert on the selection and use of a variety of technologies for biomarker assay development. At MolecularMD, an ICON plc company, biopharma clients have access to a fit-for-purpose, platform-agnostic approach leveraging technology platforms such as NGS, droplet digital PCR, and multiplexed IHC for the codevelopment of clinical trial assays and/or downstream diagnostics aligned with the therapeutic program objectives.
spacer
Marisa Pearce
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

OWEN MUMFORD LAUNCHES NEW 2-STEP SINGLE-USE AUTO-INJECTOR PLATFORM AIDAPTUS®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development.
More info >>

White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement